BTAI BioXcel Therapeutics

BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

NEW HAVEN, Conn., May 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in fireside chats at three upcoming virtual healthcare investor conferences.

Presentation Details:

Event: Jefferies Virtual Healthcare Conference

Date: Wednesday, June 2, 2021

Time: 10:30 AM ET

Event: Goldman Sachs 42nd Annual Global Healthcare Conference

Date: Wednesday, June 9, 2021

Time: 4:40 PM ET

Event: BofA Securities Napa Biopharma Conference

Date: Monday, June 14, 2021

Time: 11:30 AM ET

Live webcasts of the fireside chats will be accessible through the Investors section of the Company's website at . Following the conferences, the webcasts will be archived on the Company’s website for at least 30 days.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit .

Contact Information:

BioXcel Therapeutics, Inc.

Investor Relations:

Mary Coleman

BioXcel Therapeutics, VP of Investment Relations



1.475.238.6837

John Graziano

Solebury Trout



1.646.378.2942

Media:

Julia Deutsch

Solebury Trout



1.646.378.2967



EN
26/05/2021

Underlying

BTAIBioXcel Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioXcel Therapeutics

 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Cele...

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pivotal moment for the company — celebrating BioXcel’s breakthrough pr...

23h / 23m 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Li...

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the market value of listed securities (“MVLS”) requirement under Nasdaq Listing Rule 5550(b)(2) (the “...

September 18, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Dat...

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p

September 10, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Glo...

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference to be held September 8 - 10, 2025. Date: Monday, September 8, 2025Time: 4:30 p.m. Eastern TimeWebcast Link: The live an...

September 4, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phas...

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial ...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch